- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07948408
A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)
An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.
This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Wei Zhong, PhD
- Telefonnummer: 1-951-547-4692
- E-post: wei.zhong@wayshinebiopharm.com
Studera Kontakt Backup
- Namn: Lily Liu, MD
- Telefonnummer: +8613818880308
- E-post: lily.liu@wayshinebiopharm.com
Studieorter
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200123
- Shanghai East Hospital
-
Kontakt:
- Fei Zhou, MD
- Telefonnummer: +86 21-38804518
- E-post: fei.zhou@tongji.edu.cn
-
Huvudutredare:
- Caicun Zhou, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC
- Eligible for platinum-based doublet chemotherapy
- Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
- Tissue sample confirmed C797S positive by central lab using NGS
- At least one measurable target lesion per RECIST v1.1 criteria
- ECOG 0-1
- Adequate organ function and bone marrow function
- Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
- Male participants should agree to the use of contraceptive measures
Exclusion Criteria:
- Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
- Histological or phenotypic transformation
- Any severe or uncontrolled systemic disease
- ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
- Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
- A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
- Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
- Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
- Poorly controlled diabetes mellitus or hypertension
- History of other primary malignancies within two years
- Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
- Active infectious diseases (e.g., active HIV, HBV and HCV)
- Known alcohol or drug dependence
- Mental disorders or poor compliance
- The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: WSD0922-FU Tablet
|
Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Andra namn:
|
|
Aktiv komparator: Platinum-Based Doublet Chemotherapy
|
Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsram: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1 |
From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS)
Tidsram: From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
OS |
From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PFS as assessed by investigator per RECIST 1.1
Tidsram: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
|
Objective Response Rate (ORR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
ORR as assessed by investigator and BICR per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Duration of Response (DOR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DoR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Disease Control Rate (DCR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DCR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Disease Progression (TTP)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTP by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Response (TTR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial ORR (icORR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icORR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial PFS (icPFS)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icPFS by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DOR (icDOR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDOR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DCR (icDCR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDCR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTP (icTTP)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTP by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTR (icTTR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
AE and SAE
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
AE and SAE per CTCAE 6.0 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Caicun Zhou, MD, Shanghai East Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Neoplasmer i nervsystemet
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Neoplasmer i centrala nervsystemet
- Karcinom, icke-småcellig lunga
- Neoplasmer i hjärnan
- Aminosyror, peptider och proteiner
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Koordinationskomplex
- Guanin
- Hypoxantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyror, sur
- Aminosyror
- Aminosyror, dikarboxyl
- Platinaföreningar
- Pemetrexed
- Karboplatin
- Cisplatin
Andra studie-ID-nummer
- WSD0922-301
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .